KCNK6 Antibody(C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9Y257 |
---|---|
Clone Names | 100324112 |
Gene ID | 9424 |
---|---|
Other Names | Potassium channel subfamily K member 6, Inward rectifying potassium channel protein TWIK-2, TWIK-originated similarity sequence, KCNK6, TOSS, TWIK2 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | KCNK6 |
---|---|
Synonyms | TOSS, TWIK2 |
Function | Exhibits outward rectification in a physiological K(+) gradient and mild inward rectification in symmetrical K(+) conditions. |
Cellular Location | Membrane; Multi-pass membrane protein |
Tissue Location | Widespread expression, detected in all tissues tested except for skeletal muscle. Strongest expression in placenta, pancreas, heart, colon and spleen, lower levels detected in peripheral blood leukocytes, lung, liver, kidney and thymus. Lowest expression detected in brain |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes one of the members of the superfamily ofpotassium channel proteins containing two pore-forming P domains.This channel protein, considered an open rectifier, is widelyexpressed. It is stimulated by arachidonic acid, and inhibited byinternal acidification and volatile anaesthetics. [provided byRefSeq].
References
Sebastiani, P., et al. Am. J. Hematol. 85(1):29-35(2010)Gierten, J., et al. Br. J. Pharmacol. 154(8):1680-1690(2008)Goldstein, S.A., et al. Pharmacol. Rev. 57(4):527-540(2005)Mhatre, A.N., et al. J. Neurosci. Res. 75(1):25-31(2004)Goldstein, S.A., et al. Nat. Rev. Neurosci. 2(3):175-184(2001)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.